Jakob Benedict Seidelin

Jakob Benedict Seidelin

Clinical Professor

Member of:

  • Internal Medicine: Gastroenterology and Hepatology


  1. 2022
  2. Published

    Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalized patients with severe ulcerative colitis

    Ilvemark, J. F. K. F., Wilkens, R., Thielsen, P., Dige, A., Boysen, T., Brynskov, J., Bjerrum, Jakob Tveiten & Seidelin, Jakob Benedict, 2022, In: Journal of Crohn's & colitis. 16, 11, p. 1725–1734

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The effect of induced hyperammonaemia on sleep and melanopsin-mediated pupillary light response in patients with liver cirrhosis: A single-blinded randomized crossover trial

    Kann, A. E., Ba-Ali, S., Seidelin, Jakob Benedict, Larsen, F. S., Hamann, Steffen & Bjerring, Peter Nissen, 2022, In: PLoS ONE. 17, 9 , e0275067.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

    Pauwels, R. W. M., van der Woude, C. J., Nieboer, D., Steyerberg, E. W., Casanova, M. J., Gisbert, J. P., Kennedy, N. A., Lees, C. W., Louis, E., Molnár, T., Szántó, K., Leo, E., Bots, S., Downey, R., Lukas, M., Lin, W. C., Amiot, A., Lu, C., Roblin, X., Farkas, K. & 15 others, Seidelin, Jakob Benedict, Duijvestein, M., D'Haens, G. R., de Vries, A. C., Janneke van der Woude, C., Sleutjes, J. A. M., García-Ortiz, J. M., Brooks, A. J., Hamlin, P. J., Sebastian, S., Lobo, A. J., Dieleman, L. (. A., Ben-Horin, S., Steenholdt, Casper & CEASE Study Group, C. S. G., 2022, In: Clinical Gastroenterology and Hepatology. 20, 8, p. 1671-1686.e16

    Research output: Contribution to journalReviewResearchpeer-review

  5. Published

    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    Peyrin-Biroulet, L., Hart, A., Bossuyt, P., Long, M., Allez, M., Juillerat, P., Armuzzi, A., Loftus, E. V., Ostad-Saffari, E., Scalori, A., Oh, Y. S., Tole, S., Chai, A., Pulley, J., Lacey, S., Sandborn, W. J., Aguilar, H., Ahmad, T., Akriviadis, E., Aldeguer Mante, X. & 31 others, Altorjay, I., Ananthakrishnan, A., Andersen, V., Andreu Garcia, M., Aumais, G., Avni-Biron, I., Axler, J., Ayub, K., Baert, F., Bafutto, M., Bamias, G., Bassan, I., Baum, C., Beaugerie, L., Behm, B., Bekal, P., Bennett, M., Bermejo San Jose, F., Bernstein, C., Bettenworth, D., Bhaskar, S., Biancone, L., Bilir, B., Blaeker, M., Bloom, S., Bohman, V., Bosques Padilla, F. J., Bouhnik, Y., Seidelin, Jakob Benedict, Staun, Michael & HICKORY Study Group, H. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 2, p. 128-140 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

    Vermeire, S. & LAUREL Study Group, L. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 1, p. 28-37 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Zhao, M., Wewer, M. D., Bjerrum, Jakob Tveiten , Steenholdt, Casper, Schiødt, Frank Vinholt, Haderslev, K., Kiszka-Kanowitz, M., Munkholm, Pia, Seidelin, Jakob Benedict & Burisch, J., 2022, In: Ugeskrift for Laeger. 184, 11, V09210706.

    Research output: Contribution to journalReviewResearchpeer-review

Previous 1 2 Next

ID: 33971112